Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

NIH Payoff: Patents

Grants’ impact spills into the marketplace, study shows.

Christine Daniloff | MIT News Office

Research grants issued by the National Institutes of Health contribute to a significant number of private-sector patents in biomedicine, according to a new study coauthored by an MIT professor.

This story is part of the July/August 2017 Issue of the MIT News Magazine
See the rest of the issue
Subscribe

The study, published in Science, examines 27 years’ worth of data and finds that 31 percent of NIH grants, which are publicly funded, produce articles that are later cited by patents in the biomedical sector.

“The impact on the private sector is a lot more important in magnitude than what we might have thought before,” says coauthor Pierre Azoulay, a Sloan professor. And as the paper explains, even NIH-backed research projects cited only indirectly in later patents “demonstrate the additional reach that publicly funded science can have by building a foundation for private-sector R&D.”

After reviewing over 365,000 grants—nearly every NIH grant awarded between 1980 and 2007—the researchers also found that more than 8 percent of NIH grants generate a patent directly.

Intriguingly, the researchers discovered no significant difference between “basic” and “applied” research grants in the frequency with which they helped generate patents; both kinds of research spill over into productive private-sector uses.

“If you thought the NIH exists in an ivory tower, you’re wrong,” Azoulay says. “They are the nexus of knowledge that really unifies two worlds.”

The NIH encompasses multiple research institutes and is the world’s biggest source of public funding for biomedical research, dispensing about $32 billion annually in grants. “Grants produce papers, and papers are cited by patents [generated] by pharmaceutical firms,” says Azoulay. “It’s hard to think of [a drug] that doesn’t have a patent."

Gain the insight you need on emerging technologies at EmTech MIT.

Learn more and register
Christine Daniloff | MIT News Office
Next in MIT News
Want more award-winning journalism? Subscribe to Insider Online Only.
  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.